

IFIN



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani *et al.*

Appl. No.: 10/772,445

Filed: February 6, 2004

For: **Substituted Quinazolines and
Analogs and the Use Thereof**

Confirmation No.: 5165

Art Unit: 1615

Examiner: *To be assigned*

Atty. Docket: 1483.0340003/JMC/JSL

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/654,839, filed September 1, 2000, now U.S. Patent No. 6,465,472 B1, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Jeffrey S. Lundgren
Agent for Applicants
Registration No. 51,978

Date: Aug. 20, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

				ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445		
				FIRST NAMED INVENTOR Upasani et al.			
				FILING DATE February 6, 2004	ART UNIT 1615		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,748,331	06/24/1973	Cooke et al.			05/06/1971
	AB1	3,963,717	06/15/1976	Cooke et al.			03/10/1975
	AC1	5,284,957	02/08/1994	Huff			09/03/1992
	AD1	5,514,680	05/07/1996	Weber et al.			11/05/1993
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 94/13275	06/23/1993	WIPO			Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	1	Anderson, B.A. et al., "Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164," <i>J. Am. Chem. Soc.</i> 117:12358-12359, American Chemical Society (1995)				
	AS	1	Buchan, A.M. et al., "Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia," <i>Neuroreport</i> 2:473-476, Lippincott, Williams & Wilkins (1991)				
	AT	1	Buchan, A.M. et al., "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?" <i>Stroke Suppl. I</i> 24:I-148-I-154, Lippincott, Williams & Wilkins (1993)				
EXAMINER				/Cecilia Jaisle/		DATE CONSIDERED 01/12/2008	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
			FIRST NAMED INVENTOR Upasani et al.	
			FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	2	Choi, D.W. et al., "Glutamate Neurotoxicity in Cortical Cell Culture," <i>J. Neurosci</i> 7:357-368, Society for Neuroscience (1987)				
	AS	2	Coombs, R.V. et al., "Synthesis and Antinflammatory Activity of 1-Alkyl-4-aryl-2(1H)-quinazolinones and Quinazolinethiones," <i>J. Med. Chem.</i> 16:1237-1245, American Chemical Society (1973)				
	AT	2	Copani, A. et al., "Nootropic Drugs Positively Modulate γ -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropanoic Acid-Sensitive Glutamate Receptors in Neuronal Cultures," <i>J. Neurochem.</i> 58:1199-1204, The International Society for Neurochemistry (1992)				

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED	01/12/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1483.0340003/JMC/JSL FIRST NAMED INVENTOR Upasani et al.	APPLICATION NO. 10/772,445
		FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes
AM						No
AN						Yes
AO						No
AP						Yes

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	3	De Sarro, G. et al., "GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice," <i>Eur. J. Pharmacol.</i> 294:411-422, Elsevier Science (1995)
		Fetter, J. et al., "Electron Deficient Heteroaromatic Ammonioamides-XVI," <i>Tetrahedron</i> 34:2557-2563, Pergamon Press (1978)
AS	3	
AT	3	Graham, S.H. et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," <i>J. Pharm. Exp. Ther.</i> 276:1-4, American Society for Pharmacology and Experimental Therapeutics (1996)

EXAMINER /Cecilia Jaisle/ DATE CONSIDERED 01/12/2008
 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1483.0340003/JMC/JSL FIRST NAMED INVENTOR Upasani et al. FILING DATE February 6, 2004	APPLICATION NO. 10/772,445 ART UNIT 1615
--	--	--	---	---

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	4	Haider, N., "Convenient Synthesis of Cycloalkene-Fused Phthalazinones," <i>Heterocycles</i> 41:2519-2525, Sendai Institute of Heterocyclic Chemistry (1995)				
	AS	4	Houlihan, W.J. et al., "Antiinflammatory Properties of 8-Aryl-5-isopropyl-2H-1,3-dioxolo[4,5-g]quinazolin-6(5H)-ones and -thiones," <i>J. Med. Chem.</i> 25:1110-1113, American Chemical Society (1982)				
	AT	4	Hunter, J.C. and L. Singh, "Role of excitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat," <i>Neurosci Lett.</i> 174:217-221, Elsevier Scientific Publishers (1994)				

EXAMINER	/Cecilia Jaisle/			DATE CONSIDERED	01/12/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CJ/

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
				FIRST NAMED INVENTOR Upasani <i>et al.</i>	
				FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	5		Ikeda, A. et al., "Clinical Trial of Piracetam in Patients with Myoclonus: Nationwide Multiinstitution Study in Japan," <i>Movement Disorders</i> 11:691-700, Raven Press (1996)			
	AS	5		Iwasaki, Y. et al., "CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats," <i>J. Neurosci.</i> 134:21-25, Society for Neuroscience (1995)			
	AT	5		Jones, B.J. et al., "The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist," <i>Br. J. Pharmacol.</i> 93:985-993, Macmillan Journals Ltd. (1988)			

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED	01/12/2008
----------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CJ/

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
			FIRST NAMED INVENTOR Upasani <i>et al.</i>	
			FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	6	Keana, J.F.W. et al., "Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-Methyl-D-aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Glutamate Receptors," <i>J. Med. Chem.</i> 38:4367-4379, American Chemical Society (1995)				
	AS	6	Larson, J. et al., "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats," <i>Brain Res.</i> 738:353-356, Elsevier/North-Holland Biomedical Press (1996)				
	AT	6	Le Peillet, E. et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," <i>Brain Res.</i> 571:115-120, Elsevier/North-Holland Biomedical Press (1992)				

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED 01/12/2008
----------	------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CJ/

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1483.0340003/JMC/JSL FIRST NAMED INVENTOR Upasani <i>et al.</i> FILING DATE February 6, 2004	APPLICATION NO. 10/772,445 ART UNIT 1615
---	--	--	--	---

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Z	Lipton, S. and P.A. Rosenberg, "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders," <i>N. Engl. J. Med.</i> 330:613-622, Massachusetts Medical Society (1994)
	AS	Z	McDonald., J.W. et al., "Physiological and pathophysiological roles of excitatory amino acids during central nervous system development," <i>Brain Res. Rev.</i> 15:41-70, Elsevier Science (1990)
	AT	Z	Pelletier, J.C. et al., "Substituted 1,2-Dihydropthalazines: Potent, Selective, and Noncompetitive Inhibitors of the AMPA Receptor," <i>J. Med. Chem.</i> 39:343-346, American Chemical Society (1996)

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED	01/12/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CJ/

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes
	AM						No
	AN						Yes
	AO						No
	AP						Yes

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	8	Sang, C.N. et al., "Analgesic Effects of AMPA/Kainate Antagonist LY293558 In Human: Reduction of Capsaicin-Evoked Allodynia and Hyperalgesia But Not Pain Sensations In Normal Skin." <i>Soc. Neurosci 23:1015</i> , Abstract No. 401.14, Society of Neuroscience (October 1997)				Yes
	AS	8	Schoepp, D. et al., "Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors," <i>Trends Pharm Sci 11:508-515</i> , Elsevier in Association with the International Union of Pharmacology (1990)				No
	AT	8	Sheardown, M.J. et al., "2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxalin: A Neuroprotectant for Cerebral Ischemia," <i>Science 247:571-574</i> , American Association for the Advancement of Science (1990)				Yes

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED	01/12/2008
----------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CJ/

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	9		Sheardown, M.J. et al., "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," Eur. J. Pharmacol. 236:347-353, Elsevier Science (1993)			
	AS	9		Staubli, U. et al., "Facilitation of glutamate receptors enhances memory," Proc. Natl. Acad. Sci. USA 91:777-781, National Academy of Sciences (1994)			
	AT	9		Thomas, R.J., "Excitatory Amino Acids in Health and Disease," J. Am. Geriatr. Soc. 43:1279-1289, Blackwell Science (1995)			
EXAMINER	/Cecilia Jaisle/			DATE CONSIDERED 01/12/2008			
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CJ/

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
			FIRST NAMED INVENTOR Upasani et al.	
			FILING DATE February 6, 2004	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	10	Woodward, R.M. et al., "In Vitro Pharmacology of ACEA-1021 and ACEA-1031: Systemically Active Quinoxalinediones with High Affinity and Selectivity for N-Methyl-D-aspartate Receptor Glycine Sites," <i>Mol. Pharmacol.</i> 47:568-581, American Society for Pharmacology and Experimental Therapeutics (1995)				
	AS	10	Wrathall, J.R. et al., "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-Methyl-D-Aspartate receptors," <i>Exp. Neurology</i> 137:119-126, Academic Press (1996)				
	AT						

EXAMINER	/Cecilia Jaisle/	DATE CONSIDERED	01/12/2008
----------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CJ/



ATTORNEYS AT LAW



Robert Greene Steme
Edward J. Kessler
John M. Cowen
David K.S. Cornell
Robert W. Esmond
Tracy-Gene G. Durkin
Michael J. Fornasola
Michael B. Ray
Robert A. Solch
Eric S. Stelle
Michael Q. Lee
Steven R. Ludwig
John M. Cover
Lisa A. Green
Robert C. Milberg
Lawrence B. Bugasky
Donald J. Festenstein
Michael V. Messinger

Judith A. Kim
Timothy J. Shea, Jr.
Patricia A. Abbott
Jeffrey T. Hevery
Hedi L. Kaus
Albert L. Kaus
Donald J. Bassowit
Peter A. Jackman
Teresa U. Medler
Jeffrey A. Newell
Katherine P. Patterson
Vincent L. Capusano
Elton Ellington Floyd
Thomas J. Flory
Brian J. Del Buono
Vigil Lee Beazley
Theodore A. Wood
Elizabeth J. Haanes

Joseph S. Orsoff
Frank R. Cotttingham
Christopher J. Doherty
Ray Lynn P. Guest
George S. Bardmeier
Daniel J. Olen
Jacob D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Kline
Lukrane M. DeSantis
Ann E. Summerfield
Aric W. Lederman
Heather A. Carlson
Jeffrey A. Doyle^{*}
Gaby L. Longworth
Lori K. Gordon
Nicole D. Drera^{*}

Ted J. Ebensole
Jyoti C. Tyler
Gusta A. Vogel
Registered Patent Agents:
Carrie E. Mankiewicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Cassandra M. Quach
Bryan L. Shelton
Robert A. Schwartzman
Terence J. O'Farrell
Jeffrey S. Lurding
Victoria S. Rutherford
Michelle K. Houliak
Robert J. Bedells
Simon J. Elliott

Julie A. Heider
Mita Mukherjee
Suzanne M. Hause
Michael G. Penn
Christopher J. Walsh

Of Counsel:
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

^{*}Admitted only in Maryland
[#]Admitted only in Virginia
+Practice limited to Federal Agencies

August 20, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8787
INTERNET ADDRESS:
LUNDOREN@SKGP.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1615

Re: U.S. Utility Patent Application
Application No. 10/772,445; Filed: February 6, 2004
For: Substituted Quinazolines and Analogs and the Use Thereof
Inventors: Upasani *et al.*
Our Ref: 1483.0340003/JMC/JSL

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449 citing documents on Information Disclosure Statement (AA1-AD1, AL1, AR1-AT1, AR2-AT2, AR3-AT3, AR4-AT4, AR5-AT5, AR6-AT6, AR7-AT7, AR8-AT8, AR9-AT9, AR10, AS10);
3. First Supplemental Information Disclosure Statement;
4. Form PTO-1449 citing documents on First Supplemental Form PTO-1449 citing documents (AE1-AH1, AM1-AP1, AT10, AL2);
5. Second Supplemental Information Disclosure Statement;
6. Form PTO-1449 citing documents on Second Supplemental Form PTO-1449 citing documents (AM2, and AR11-AT11); and
7. Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
August 20, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Jeffrey S. Lundgren
Agent for Applicants
Registration No. 51,978

JSL/asl
Enclosures

301903v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani *et al.*

Appl. No.: 10/772,445

Filed: February 6, 2004

For: **Substituted Quinazolines and
Analogs and the Use Thereof**

Confirmation No.: 5165

Art Unit: 1615

Examiner: *To be assigned*

Atty. Docket: 1483.0340003/JMC/JSL

First Supplemental Information Disclosure Statement

Under 37 C.F.R. § 1.97(b)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering of this First Supplemental Information Disclosure Statement is a continuation of Applicants' Information Disclosure Statement filed herewith, in connection with the above-captioned application.

Copies of documents AE1 to AH1, AM1 to AL2, and AT10 were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/654,839, filed September 1, 2000, now U.S. Patent No. 6,465,472 B1, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document AN1 cited on Form PTO 1449:

Document AN1 is in a foreign language. An English language abstract of document AN1 is attached as document AT10.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jeffrey S. Lundgren
Agent for Applicants
Registration No. 51,978

Date: Aug. 20, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1483.0340003/JMC/JSL FIRST NAMED INVENTOR Upasani <i>et al.</i> FILING DATE February 6, 2004	APPLICATION NO. 10/772,445 ART UNIT 1516		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE1	3,759,920	09/18/1973	Linder <i>et al.</i>			06/24/1971
	AF1	3,856,960	12/24/1974	Cooke <i>et al.</i>			04/13/1973
	AG1	4,224,328	09/23/1980	Takesue			04/11/1979
	AH1	5,650,410	07/22/1997	Sohda <i>et al.</i>			04/17/1995
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM1	DE 2 058 722	06/09/1971	Germany			X Yes No
	AN1	DE 2 307 808	08/30/1973	Germany			Yes X No
	AO1	GB 1341401	12/19/1993	Great Britain			Yes No
	AP1	EP 0 567 107 A1	10/27/1993	Europe			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR						
	AS						
			Dialog File 351, Accession No. 1973-41080U/197329, Derwent WPI English language abstract for DE 2 307 808 (Document AN1)				
EXAMINER /Cecilia Jaisle/					DATE CONSIDERED 01/12/2008		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		FIRST NAMED INVENTOR Upasani et al.	
		FILING DATE February 6, 2004	ART UNIT 1516

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL2	EP 0 634 169 A1	01/18/1995	Europe			Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		
AS		
AT		

EXAMINER /Cecilia Jaisle/ DATE CONSIDERED 01/12/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Copy

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani *et al.*

Appl. No.: 10/772,445

Filed: February 6, 2004

For: **Substituted Quinazolines and
Analogs and the Use Thereof**

Confirmation No.: 5165

Art Unit: 1615

Examiner: *To be assigned*

Atty. Docket: 1483.0340003/JMC/JSL

Second Supplemental Information Disclosure Statement

Under 37 C.F.R. § 1.97(b)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering of this Second Supplemental Information Disclosure Statement is a continuation of Applicants' First Information Disclosure Statement filed herewith, in connection with the above-captioned application.

Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 10/219,755, filed August 16, 2002, now U.S. Patent No. 6,765,006 B2, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document AM2 cited on Form PTO 1449:

Document AM2 is in a foreign language. An English language translation of document AM2 is attached as document AR11.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jeffrey S. Lundgren
Agent for Applicants
Registration No. 51,978

Date: Aug. 20, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION Disclosure STATEMENT		O I P E AUG 20 2004 SEARCHED INDEXED SERIALIZED FILED U.S. PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445		
				FIRST NAMED INVENTOR Upasani et al.	FILING DATE February 6, 2004		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
AA							
AB							
AC							
AD							
AC							
AC							
AC							
AH							
AI							
AJ							
AK							
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
AL						Yes No	
AM2	JP S51-8287	01/23/1976	Japan			X Yes No	
AN						Yes No	
AO						Yes No	
AP						Yes No	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
AR	11	English language translation of Japanese Unexamined Patent Application No. JP S51-8287 published January 23, 1976, 7 pages. (Document AM2)					
AS	11	Yamamoto, M., et al., "Quinazolin-2-ones from 3,4-dihydroquinazolin-2-ones," Chem. Abstr. 84:566, Abstract No. 180277m, American Chemical Society (1976)					
AT	11	Supplementary Partial European Search Report for European Application No. EP99911063 filed on March 2, 1999					
EXAMINER /Cecilia Jaisle/				DATE CONSIDERED 01/12/2008			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							